FDA Cites Amphastar Subsidiary for Manufacturing Practice Violations

The U.S. Food and Drug Administration (FDA) has issued a warning letter to International Medication Systems (IMS), a subsidiary of Amphastar Pharmaceuticals. The letter details multiple violations of current Good Manufacturing Practice regulations at its California facility, including issues with environmental monitoring and investigation procedures. While production continues, IMS is reportedly implementing a remediation plan to address the FDA's concerns.